Brain Metastases
Conditions
Keywords
Treatment
Brief summary
The overall aim and primary outcome of this study will be a descriptive analysis of the current treatment practice of BM in Norway. Specifically, it may give answers to the following research questions: * What is the true incidence of BM in Norway? * How are patients with BM treated at present? * Do treatments differ between hospitals? * How do treatments impact quality of life of the patients? * Which factors (treatment, tumor and host variables) can explain disease control, survival, symptom relief, and general functions? * How can BM staging be improved?
Interventions
None listed
Sponsors
Norwegian Cancer Society
South-Eastern Norway Regional Health Authority
Oslo University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Verified cancer diagnosis of solid tumors (based on radiological, histological/cytological or operative evidence). * Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or surgical biopsies * Age ≥ 18 years * Able to comply with study procedures * Able to provide written informed consent after information in Norwegian
Exclusion criteria
* Primary brain tumors * Primary hematological malignancies (lymphomas, leukemias) * Previous diagnosis and/or treatment of BM * Unable to produce written informed consent after information in Norwegian
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival after diagnosis of brain metastases | Time from diagnosis of brain metastases till death of any cause, assessed up to 12 months | Calculation of the overall survival times for each patient enrolled |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment offered to patients diagnosed with brain metastases | 3 years | Description of treatment offered |
| Changes in patient reported symptoms and quality of life items through EORTC questionnaire QLQ PAL15 and submodule BN20 | Monthly up to 12 months after inclusion | Description of changes in patient reported outcomes through standardized questionnaires.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients receiving palliative care (EORTC QLQ-C15-PAL), covers items such as pain, physical and emotional functioning. The QLQ-BN20 contains questions on 7 single-item symptom scales (headaches, seizures, drowsiness, hair loss, itchy skin, leg weakness, and bladder control), and 4 multi-item scales (future uncertainty, visual disorder, motor dysfunction, and communication deficit). Patient's scores are translated into a scale from 1-100. A change of 10 points in one item is considered clinically significant. |
Countries
Norway
Outcome results
None listed